1. Background
=============

Snakebite is a serious condition requiring rapid treatment procedures. Among the 3,500 known snake species, less than 10% are poisonous. Venomous snakebites in children are uncommon but have the potential for significant morbidity and occasional mortality. About 3,000,000 snakebite cases and 150,000 deaths due to snakebites are recorded annually worldwide ([@A5212REF1]-[@A5212REF3]). Mortality due to snakebite nearly reached 25% in previous years, but it decreased to below 0.5% through the easy access to antivenom and the development of emergency interventions ([@A5212REF1]). In Turkey, snakebite cases are common especially in the Southeastern Anatolia region because of its climatic and geographical characteristics. The most common kind of snake in this region is *Viperidae lebetina* ([@A5212REF3]). Viperidae venom has necrotizing and hemorrhagic effects ([@A5212REF3]). The clinical course of snakebite is more severe and more complicated in children than in adults. No studies on snakebites have been conducted among the pediatric population in Turkey.

2. Objectives
=============

This study aimed to investigate the demographic characteristics, severity of snakebite, laboratory findings, complications, and risk factors of prolonged hospitalization and clinical severity of snakebite in children.

3. Patients and Methods
=======================

This retrospective study was performed by Dicle University department of pediatrics. Our hospital is a referral hospital in Southeast Anatolia in Turkey. The information of all patients with a history of snakebite between June 2006 and August 2015 was obtained from hospital records.

A total of 151 children with snakebite were enrolled in the study. The condition of snakebite patients admitted to the hospital was monitored from the time of admission to the end of their hospital stay. The included cases were further confirmed on the basis of the clinical symptoms of local swelling and hemotoxicity.

Patient data were obtained from the patient follow-up forms completed at admission and from hospital records. Age, gender, location of bite, duration of hospitalization (days), severity of envenomation, symptoms and clinical findings, electrocardiogram for T wave crash, laboratory data, specific treatment approaches (dose of snake toxin antiserum, plaster and splint, and antibiotics), complications, and outcomes were evaluated.

Laboratory data included hemogram parameters such as first, fifth, and tenth day of white blood cell (WBC) count; hemoglobin (Hb); platelet count; and biochemical parameters such as urea, creatinine, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, creatine kinase (CK), and prothrombin time at admission were recorded.

Demographic features, hemogram, and biochemical parameters were compared according to the severity of envenomation in the study group. Mild envenomation is defined as swelling involving one or two segments of the bitten limb and less than a 4 cm increase in limb circumference with no bleeding at the bite site, as well as no necrosis or systemic symptoms. Moderate envenomation is defined as swelling involving two or three segments of the bitten limb and more than 4 cm increase in limb circumference with local bleeding at the bite site, no local necrosis, and minimal or no systemic symptoms. Severe envenomation results in swelling extending beyond the bitten limb (to the trunk), blisters, local bleeding, necrosis or compartment syndrome, and clinical systemic signs (multiple systemic bleeding, hypotension or shock, disseminated intravascular coagulation or renal failure, cerebral hemorrhage, or multi-systemic failure) ([@A5212REF4]).

Patients who did not have bite marks of a snake and any other forms of unknown bites that were not snakebites, were over 18 years old, and whose file records were inaccessible were excluded from the study.

The study protocol was approved by the non-interventional clinical research ethics committee of Dicle University medical faculty.

3.1. Statistical Analysis
-------------------------

The data were analyzed using the statistical package for social sciences version 18.0 program for Windows. The Kolmogorov-Smirnov test was used to determine whether or not the numerical variables exhibited normal distribution. Variables with normal distribution were expressed as mean ± standard deviation, whereas variables without normal distribution were expressed as median (minimum--maximum) values. Independent groups were compared using Student's t-test. Categorical variables were analyzed using the chi-square test. Friedman's test was used to compare the distributions of two or more quantitative variables. Cumulative incidence was calculated for the entire duration of the study with 95% confidence intervals. P values \< 0.05 (two-sided, where applicable) were considered statistically significant.

4. Results
==========

A total of 151 children with snakebite were enrolled in the study. Among them, 99 (65.6%) were male and the average age was 119.6 ± 37.8 months. The most frequent area of occurrence was the rural area at 65.6% (n = 99). The most common location of the bites was the right forearm at 61.6% (n = 93). Among the patients, 32 (21.2%) had mild, 73 (48.3%) had moderate, and 46 (30.5%) had severe snakebites. The median duration of hospitalization was 6 (1 - 26) days. The most common findings from the physical examination of the patients were edema, ecchymosis, necrosis, and tachycardia. The most common complication was compartment syndrome at a rate of 28.5% (n = 43), and all patients were discharged without any complications. The median administered snake antivenom was 1 (1 - 5) dose. A plaster splint was applied to 48 (31.8%) patients, and 145 (96.0%) patients received prophylactic treatment with antibiotics. No fatalities were reported in the study. An overview of demographic features, clinical features on admission, treatment, and outcomes of the patients is summarized in [Table 1](#A5212TBL1){ref-type="table"}.

###### Demographic Features, Clinical Features on Admission, Treatment, and Outcomes in Patients With Snakebites (n = 151).

  Clinical Features of Snakebite       Values^[a](#A5212TBL1FN1){ref-type="table-fn"}^
  ------------------------------------ -------------------------------------------------
  **Average age, mo**                  119.6 ± 37.8
  **Gender**                           
  Male                                 99 (65.6)
  Female                               52 (34.4)
  **Area of occurrence**               
  Rural area                           99 (65.6)
  Urban area                           52 (34.4)
  **Location of bite site**            
  Right forearm                        93 (61.6)
  Right foot                           27 (17.9)
  Right hand                           9 (6.0)
  Left foot                            9 (6.0)
  Left hand                            5 (3.3)
  Left hip                             4 (2.6)
  Left shoulder                        2 (1.3)
  Left leg                             1 (0.7)
  Right leg                            1 (0.7)
  **Duration of hospitalization, d**   6 (1 - 26)
  **Severity of Envenomation**         
  Mild                                 32 (21.2)
  Moderate                             73 (48.3)
  Severe                               46 (30.5)
  **Symptoms and clinical findings**   
  Edema                                143 (94.7)
  Ecchymosis                           112 (74.2)
  Necrosis                             45 (29.8)
  Tachycardia                          34 (22.5)
  Vesicle or bulla                     32 (21.2)
  Dyspnea                              32 (21.2)
  Hypotension                          29 (19.2)
  Electrocardiogram changes            11 (7.3)
  **Treatment**                        
  Antivenom dose, median               1 (1 - 5)
  Plaster splints                      48 (31.8)
  Prophylactic antibiotic              145 (96.0)
  **Clinical outcomes**                
  Non-complicated recovery             108 (71.5)
  Complication                         43 (28.5)
  Mortality                            \-

^a^Values are expressed as mean ± standard deviation, median range or No. (%)

Duration of hospitalization (P \< 0.001), rural occurrence (P \< 0.001), WBC (P = 0.002), AST/ALT ratio (P = 0.010), CK (P \< 0.001), hypoproteinemia (P = 0.001), hypoalbuminemia (P \< 0.001), and hypocalcemia (P = 0.005) were significantly high in the severe snakebite group ([Table 2](#A5212TBL2){ref-type="table"}). No statistically significant differences were found among the severity group in terms of age, gender, hemoglobin, platelet count, urea, creatine, and prothrombin time values (P \> 0.05) ([Table 2](#A5212TBL2){ref-type="table"}).

###### Demographic Features and Laboratory Findings of Snakebite Severity Groups

  Demographic Features                   Mild (n = 32)    Moderate (n = 73)   Severe (n = 46)   P Value
  -------------------------------------- ---------------- ------------------- ----------------- ----------
  **Age, mo**                            131 (36 - 190)   120 (25 - 180)      132 (25 - 190)    0.725
  **Gender**                                                                                    0.695
  Female                                 11 (34.3)        23 (31.5)           18 (39.1)         
  Male                                   21 (65.7)        50 (68.5)           28 (60.9)         
  **Area of occurrence**                                                                        0.001
  Rural area                             21 (65.7)        36 (49.3)           42 (91.3)         
  Urban area                             11 (34.3)        37 (50.7)           4 (8.7)           
  **Duration of hospitalization, d**     4 (1 - 13)       5 (1 - 20)          9 (1 - 26)        \< 0.001
  **Laboratory findings at admission**                                                          
  WBC, K/uL                              11.1 ± 4.6       15.0 ± 6.5          16.7 ± 7.8        0.002
  Hemoglobin, g/dL                       12.8 ± 1.2       13.4 ± 1.5          13.1 ± 2.5        0.163
  Platelet count, K/uL                   291 ± 82         296 ± 101           265 ± 106         0.154
  Urea, mg/dL                            26.4 ± 9.8       27.4 ± 8.9          29.1 ± 11.7       0.812
  Creatine, mg/dL                        0.5 ± 0.1        0.5 ± 0.2           0.5 ± 0.2         0.302
  Calcium, mg/dL                         9.3 ± 0.6        9.4 ± 1.0           8.8 ± 0.8         0.005
  AST/ALT ratio, U/L                     1.5 ± 0.5        1.8 ± 0.6           2.1 ± 0.8         0.010
  Total Protein, g/dL                    7.0 ± 0.7        6.7 ± 0.8           6.2 ± 1.0         0.001
  Albumin, g/dL                          3.9 ± 0.4        3.8 ± 0.3           3.3 ± 0.6         \< 0.001
  CK, U/L                                169 ± 136        243 ± 204           535 ± 598         0.001
  PT, sn                                 13.6 ± 2.5       14.0 ± 3.3          13.1 ± 3.5        0.516

Abbreviations: AST/ALT ratio, aspartate aminotransferase to alanine aminotransferase ratio; CK, creatine kinase; PT, prothrombin time; SD, standard deviation; WBC, white blood cell.

WBC (P = 0.006) and AST/ALT ratio (P = 0.018) were significantly higher on the first day of the snakebite than on subsequent days ([Table 3](#A5212TBL3){ref-type="table"}).

###### Comparison of Laboratory Findings of Patients According to 1 Day, 5 Days, and 10 Days^[a](#A5212TBL3FN2){ref-type="table-fn"}^

  Parameters                 1 Day        5 Days      10 Days      P Value
  -------------------------- ------------ ----------- ------------ ---------
  **WBC, K/uL**              15.7 ± 5.4   9.9 ±3.5    10.3 ± 6.7   0.006
  **Platelet count, K/uL**   258 ± 113    193 ± 96    257 ± 108    0.510
  **AST/ALT ratio, U/L**     1.8 ± 0.7    1.6 ± 0.7   \-           0.018

Abbreviations: AST/ALT ratio, aspartate aminotransferase to alanine aminotransferase ratio; SD, standard deviation; WBC, white blood cell.

^a^Values are expressed as mean ± SD.

5. Discussion
=============

Snake venom has many effects, and the most common of which is hematotoxicity. Patients can develop local or systemic symptoms depending on the severity of the venom toxin ([@A5212REF5]-[@A5212REF7]). Pain, increased temperature, edema, ecchymosis, hemorrhage, tissue necrosis, and systemic findings such as fever, nausea, vomiting, circulatory collapse, jaundice, convulsion, and coma may develop ([@A5212REF4], [@A5212REF8]). Tekin et al. monitored 123 pediatric patients with snakebite and found that the most common findings were edema, ecchymosis, and vesicular lesions ([@A5212REF3]). In the present study, the most common findings were edema, ecchymosis, necrosis, and tachycardia.

Snakebites are mostly seen in the lower extremities. Snakebites on the head and on the body cause two to three times greater threat to life than those in the extremities ([@A5212REF2], [@A5212REF9]). Kshirsagar et al. reported that the most common locations of the bites were the right forearm and foot ([@A5212REF10]). In our study, the most common locations of snakebites were also the right forearm and foot. This finding may be related to the more human activities for agriculture in rural areas.

The clinical severity of the reaction to snakebite depends on its location, depth, amount of venom injected, species and size of the snake involved, age and size of the victim, and victim's sensitivity to the venom ([@A5212REF5], [@A5212REF8], [@A5212REF11]). Feitosa et al. found that age ≤ 15 years, delayed medical treatment \> 6 hours, and rural workers bitten by snakes were independently associated with the risk of developing severity and mortality ([@A5212REF12]). Ogunfowokan et al. found that a delay in antivenom administration was also a risk factor for the severity of snakebites ([@A5212REF13]). In the present study, most of the patients had moderate and then severe clinical presentation due to delays in reaching the central hospital from their rural areas or hospitals. This result is considered to be due to the fact that the patients in the rural areas know what to do. They immediately seek treatment for snakebite, but some local hospitals fail to have sufficient equipment and drugs such as antivenom in store. Currently, no adequate data on medical treatment are available for our study.

After snakebite, complications such as cellulitis, disseminated intravascular coagulation, pulmonary edema, acute renal failure, compartment syndrome, and death may occur. Compartment syndrome is a rare complication resulting in the loss of function due to ischemia and extremity amputation if untreated ([@A5212REF2], [@A5212REF9]). Halesha et al. reported that respiratory insufficiency and renal failure were the more frequent complications of snakebites ([@A5212REF14]). Therefore, researchers believe that the administration of medical treatments such as elevation and antibiotics, whenever necessary, should be held off until the clinical findings are completely settled, and that fasciotomy should be performed when clinically suspected. Abbey et al. monitored 90 patients with snakebites and found 31 patients had complications and 20 patients required surgical intervention ([@A5212REF15]). In the present study, a plaster splint was applied to 31.8% of the patients, and fasciotomy was performed in all cases that developed compartment syndrome. In our study, 28.5% of the children developed compartment syndrome, and this rate is higher than that in the general literature. Researchers believe that this finding is due to the fact that compartment syndrome mostly occurs in moderate and severe cases, and that most of these cases had delayed admittance to the hospital ([@A5212REF2], [@A5212REF9]).

Baseline laboratory tests should include a complete blood count with platelet count, electrolytes, blood urea nitrogen, and prothrombin time ([@A5212REF16]). Campbell et al. reported that leukocytosis recovered on the first day of the follow-up, but thrombocyte count and hemoglobin amount were reduced ([@A5212REF6]). In the current study, leukocytosis and neutrophilia were significantly higher in the severe snakebite group than in other groups. However, in terms of hemoglobin, platelet count, urea, creatine, and prothrombin time, no statistically significant difference was observed among the subgroups of snakebite severity. Similar to previous studies, WBC and hemoglobin amounts decreased on subsequent days among snakebite patients in our study.

Snake venom that causes rhabdomyolysis may result in myoglobinuria, hyperphosphatemia, hyperpotassemia, hypoproteinemia, hypoalbuminemia, hypocalcemia, and elevated serum AST and creatinine phosphokinase levels ([@A5212REF1], [@A5212REF9]). In the present study, elevated AST, ALT, creatinine phosphokinase, hypoproteinemia, hypoalbuminemia, and hypocalcemia were observed more frequently in the severe group than in others.

Several authors have recommended abandoning prophylactic antibiotic treatment because of the risk of wound infection if viper envenomation is low. The venom effects of blistering and swelling are commonly mistaken for bacterial infection ([@A5212REF5], [@A5212REF11], [@A5212REF17]). Alkaabi et al. suggested that increased infection parameters should be evaluated for starting antibiotics in patients with fever in the presence of necrosis or abscess ([@A5212REF7]). Tekin et al. reported that all of the pediatric patients with snakebite received prophylactic treatment with antibiotics, whereas 62 (37.1%) adult patients with snakebite received antimicrobial treatments because of soft tissue infection ([@A5212REF3]). In our study, 96% of the patients received prophylactic antibiotic treatment. However, in our cases, the decision to use such a high quantity of antibiotics might have been based on their symptoms and findings. For this reason, we believe that some of the patients might have received antibiotics unnecessarily. Therefore, we propose that randomized controlled trials should be conducted to determine the efficacy of prophylactic antibiotic treatment in snakebites.

The use of heparin, steroids, antibiotics, and routine vaccination against tetanus were frequent in snakebite cases in the past ([@A5212REF8], [@A5212REF16]). Currently, the primary treatment consists of antivenom, bleeding, pain management, and surgical interventions if necessary. Our records did not include detailed data for the use of tetanus toxoid. The administration and dose of antivenom should be determined on the basis of disease severity, location of the bite, and size of the patient. Children receive a higher dose of venom because of their relatively smaller size ([@A5212REF7], [@A5212REF18]). Campbell et al. monitored 114 pediatric patients with snakebite and used antivenom only in 6% of cases, and no mortality was found in their study ([@A5212REF6]). Abbey et al. reported that 88 of 90 patients received a median of 10 vials of antivenom that was well tolerated and that none of the patients died ([@A5212REF15]). In the present study, patients received one dose of antivenom on average, but those who had moderate or severe presentation received five doses. Furthermore, no side effects of the antivenom injection and no fatalities were observed in our study. Researchers still recommend administering antivenom to patients admitted due to snakebites and believe that multi-center, randomized, controlled trials are required in the non-administration of antivenom.

Our study has several limitations: 1) it is a retrospective study with a relatively small sample size. 2) We have no data on laboratory parameters on the following days, and thus we could not compare more parameters and conduct statistical analysis. 3) A large amount of prophylactic antibiotic treatment could have affected some laboratory parameters on the following days.

In conclusion, snakebites are a life-threatening condition that can lead to prolonged hospitalization because of the impairment of laboratory parameters, soft tissue infection, compartment syndrome, and disseminated intravascular coagulopathy. Earlier treatment with antivenom and closed monitoring of clinical status and laboratory parameters such as WBC, AST, and ALT levels have decreased prolonged hospitalization, morbidity, and mortality in patients with snakebite.
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